Cargando…
Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain
Chronic pain is a common detrimental condition that affects around 20% of the world population. The current drugs to treat chronic pain states, especially neuropathic pain, have a limited clinical efficiency and present significant adverse effects that complicates their regular use. Recent studies h...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079299/ https://www.ncbi.nlm.nih.gov/pubmed/32218730 http://dx.doi.org/10.3389/fphar.2020.00167 |
_version_ | 1783507795740459008 |
---|---|
author | Lara, César O. Burgos, Carlos F. Moraga-Cid, Gustavo Carrasco, Mónica A. Yévenes, Gonzalo E. |
author_facet | Lara, César O. Burgos, Carlos F. Moraga-Cid, Gustavo Carrasco, Mónica A. Yévenes, Gonzalo E. |
author_sort | Lara, César O. |
collection | PubMed |
description | Chronic pain is a common detrimental condition that affects around 20% of the world population. The current drugs to treat chronic pain states, especially neuropathic pain, have a limited clinical efficiency and present significant adverse effects that complicates their regular use. Recent studies have proposed new therapeutic strategies focused on the pharmacological modulation of G-protein-coupled receptors, transporters, enzymes, and ion channels expressed on the nociceptive pathways. The present work intends to summarize recent advances on the pharmacological modulation of pentameric ligand-gated ion channels, which plays a key role in pain processing. Experimental data have shown that novel allosteric modulators targeting the excitatory nicotinic acetylcholine receptor, as well as the inhibitory GABA(A) and glycine receptors, reverse chronic pain-related behaviors in preclinical assays. Collectively, these evidences strongly suggest the pharmacological modulation of pentameric ligand-gated ion channels is a promising strategy towards the development of novel therapeutics to treat chronic pain states in humans. |
format | Online Article Text |
id | pubmed-7079299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70792992020-03-26 Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain Lara, César O. Burgos, Carlos F. Moraga-Cid, Gustavo Carrasco, Mónica A. Yévenes, Gonzalo E. Front Pharmacol Pharmacology Chronic pain is a common detrimental condition that affects around 20% of the world population. The current drugs to treat chronic pain states, especially neuropathic pain, have a limited clinical efficiency and present significant adverse effects that complicates their regular use. Recent studies have proposed new therapeutic strategies focused on the pharmacological modulation of G-protein-coupled receptors, transporters, enzymes, and ion channels expressed on the nociceptive pathways. The present work intends to summarize recent advances on the pharmacological modulation of pentameric ligand-gated ion channels, which plays a key role in pain processing. Experimental data have shown that novel allosteric modulators targeting the excitatory nicotinic acetylcholine receptor, as well as the inhibitory GABA(A) and glycine receptors, reverse chronic pain-related behaviors in preclinical assays. Collectively, these evidences strongly suggest the pharmacological modulation of pentameric ligand-gated ion channels is a promising strategy towards the development of novel therapeutics to treat chronic pain states in humans. Frontiers Media S.A. 2020-03-03 /pmc/articles/PMC7079299/ /pubmed/32218730 http://dx.doi.org/10.3389/fphar.2020.00167 Text en Copyright © 2020 Lara, Burgos, Moraga-Cid, Carrasco and Yévenes http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Lara, César O. Burgos, Carlos F. Moraga-Cid, Gustavo Carrasco, Mónica A. Yévenes, Gonzalo E. Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain |
title | Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain |
title_full | Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain |
title_fullStr | Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain |
title_full_unstemmed | Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain |
title_short | Pentameric Ligand-Gated Ion Channels as Pharmacological Targets Against Chronic Pain |
title_sort | pentameric ligand-gated ion channels as pharmacological targets against chronic pain |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079299/ https://www.ncbi.nlm.nih.gov/pubmed/32218730 http://dx.doi.org/10.3389/fphar.2020.00167 |
work_keys_str_mv | AT laracesaro pentamericligandgatedionchannelsaspharmacologicaltargetsagainstchronicpain AT burgoscarlosf pentamericligandgatedionchannelsaspharmacologicaltargetsagainstchronicpain AT moragacidgustavo pentamericligandgatedionchannelsaspharmacologicaltargetsagainstchronicpain AT carrascomonicaa pentamericligandgatedionchannelsaspharmacologicaltargetsagainstchronicpain AT yevenesgonzaloe pentamericligandgatedionchannelsaspharmacologicaltargetsagainstchronicpain |